References

oncotomsk

Сибирский онкологический журнал

Siberian journal of oncology

1814-48612312-3168

Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences

10.21294/1814-4861-2018-17-4-5-13

oncotomsk-809

Research Article

ЛАБОРАТОРНЫЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ

LABORATORY AND EXPERIMENTAL STUDIES

КАНЦЕРОГЕННОСТЬ МАЛАТИОНА И ЭСТРОГЕНА НА ЭКСПЕРИМЕНТАЛЬНОЙ МОДЕЛИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ У КРЫС

CARCINOGENICITY OF MALATHION AND ESTROGEN IN AN EXPERIMENTAL RAT MAMMARY GLAND MODEL

Calaf

G. M.

Calaf

G. M.

Арика, Авеню Сенадор Луис Валенте Росси, 1501

США, 10032, г. Нью-Йорк, Западная 168-я улица, 630

кандидат медицинских наук, Центр радиологических исследований, Медицинский центр Колумбийского университета (Нью-Йорк, США)

1501, Av. Senador Luis Valente Rossi, Arica, Chile

630, West 168th Street, 10032-New York, USA

PhD, Instituto de Alta Investigación Universidad de Tarapaca (Arica, Chile)

gmc24@cumc.columbia.edu

Университет Тарапаки Центр радиологических исследований, Медицинский центр Колумбийского университетаЧилиInstituto de Alta Investigación, Universidad de Tarapaca Center for Radiological Research, Columbia University Medical CenterChile

2018

01092018

174513

2018

Calaf G.M.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.siboncoj.ru/jour/article/view/809

Рак молочной железы является самой распространенной злокачественной опухолью среди женщин как в развитых, так и в развивающихся странах. Этиология рака молочной железы всё еще остается не до конца изученной. Химические вещества, такие как фосфорорганическое соединение – малатион (карбофос), используемый для борьбы с вредителями растений, являются этиологическими факторами для рака молочной железы. Связь между инициацией рака молочной железы и длительным воздействием эстрогена позволяет предпологать, что этот гормон может также играть этиологическую роль в этом процессе. Тем не менее ключевые факторы, лежащие в основе формирования рака молочной железы, еще предстоит установить. Влияние таких субстанций, как малатион и эстроген, анализировалось в экспериментальной модели молочной железы у крыс. Различные цитоплазматические белки играют ключевую роль в превращении нормальной клетки в злокачественную, и среди них есть семейство Ras-super и Ras- гомологичный A (Rho-A). Уровень этих белков был выше у животных, получавших малатион, чем у животных, получавших эстроген. E-кадгерины составляют большое семейство мембранных белков.

Результаты исследования показали, что экспрессия E-кадгерина и виментина была выше, чем экспрессия белков c-Ha-ras и Rho-A у крыс, получавших эстрогены. При раке молочной железы иммуногистохимический анализ является важным компонентом рутинных патологических исследований и играет существенную роль в диагностической и прогностической оценке тяжести заболевания.

Целью настоящего исследования было выявление прогностических маркеров для пациентов с раком молочной железы.

Breast cancer is considered a major and common health problem in both developing and developed countries. The etiology of breast cancer, the most frequent malignancy diagnosed in women in the western world, has remained unidentified. Chemicals as the organophosphorous pesticide malathion have been used to control a wide range of sucking and chewing pests of field crops, and are involved in the etiology of breast cancers. The association between breast cancer initiation and prolonged exposure to estrogen suggests that this hormone may also have an etiologic role in such a process. However, the key factors behind the initiation of breast cancer remain to be elucidated. The effect of environmental substances, such as malathion and estrogen was analyzed in an experimental rat mammary gland model. Different cytoplasmic proteins are key in the transformation of a normal cell to a malignant tumor cell and among these are the Ras super family and Ras homologous A (Rho-A). Both types of proteins were greater in animals treated with malathion than those with estrogens. E-Cadherins constitute a large family of cell surface proteins.

Results showed greater expression of E-Cadherin and vimentin than c-Ha-ras and Rho-A in rats treated by estrogens. In breast cancer, analysis using immunohistochemical markers is an essential component of routine pathological examinations, and plays an important role in the management of the disease by providing diagnostic and prognostic strategies.

The aim of the present study was to identify markers that can be used as a prognostic tool for breast cancer patients.

канцерогенезкрысымолочная железамалатионэстрогенэтиологиябелки

carcinogenesisratmammary glandmalathionestrogenetiologyproteins

References1

Perera F.P. Environment and cancer: who are susceptible? Science. 1997; 278(5340): 1068-1073.

Cabello G., Valenzuela M., Vilaxa A., Duran V., Rudolph I., Hrepic N., Calaf G. A rat mammary tumor model induced by the organophosphorous pesticides parathion and malathion, possibly through acetylcholinesterase inhibition. Environ Health Perspect. 2001 May; 109(5): 4719.

Knower K.C., To S.Q., Leung Y.K., Ho S.M., Clyne C.D. Endocrine disruption of the epigenome: a breast cancer link. Endocr Relat Cancer. 2014 Mar 12; 21(2): T3355. doi: 10.1530/ERC-13-0513.

IARC. IARC working group on the evaluation of carcinogenic risksto humans. IARC Monogr Eval Carcinog Risks Hum. 1994; 61: 45119.

Guyton K.Z., Loomis D., Grosse Y., El Ghissassi F., Benbrahim-Tallaa L., Guha N., Scoccianti C., Mattock H., Straif K.; International Agency for Research on Cancer Monograph Working Group, IARC, Lyon, France. Carcinogenicity of tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate. Lancet Oncol. 2015 May; 16(5): 4901. doi: 10.1016/S1470-2045(15)70134-8.

Calaf G.M., Roy D. Human drug metabolism genes in parathion-and estrogen-treated breast cells. Int J Mol Med. 2007; 20(6): 875881.7

Falck F.Jr., Ricci A.Jr., Wolff M.S., Godbold J., Deckers P. Pesticides and polychlorinated biphenyl residues in human breast lipids and their relation to breast cancer. Arch Environ Health. 1992 Mar-Apr; 47(2): 1436.

Wolff M.S., Toniolo P.G., Lee E.W., Rivera M., Dubin N. Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst. 1993; 85(8): 648652.

Zham S.H., Ward M.H., Blair A. Pesticides and cancer. Occupational Medicine: State of the Art Reviews. Philadelphia, PA: Hanley and Belfus Inc., 1997; 269289.

Blair A., Dosemeci M., Heineman E.F. Cancer and other causes of death among male and female farmers from twenty-three states. Am J Ind Med. 1993; 23(5): 729742.

McDuffie H.H. Women at work: agriculture and pesticides. J Occup Med. 1994 Nov; 36(11): 12406.

Calaf G.M., Garrido F. Catechol estrogens as biomarkers for mammary gland cancer. Int J Oncol. 2011 Jul; 39(1): 17783. doi: 10.3892/ijo.2011.1008.

Calaf G.M., Echiburu-Chau C. Synergistic effect of malathion and estrogen on mammary gland carcinogenesis. Oncol Rep. 2012 Aug; 28(2): 6406. doi: 10.3892/or.2012.1817.

Russo J., Russo I.H. Mammary tumorigenesis. Prog Exp Tumor Res 1991; 33: 175191.

Wellings S.R., Jensen H.M., Marcum R.G. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst. 1975; 55(2): 231273.

Aznar S., Lacal J.C. Rho signals to cell growth and apoptosis. Cancer Lett. 2001; 165(1): 110.

Schmitz A.A., Govek E.E., Bottner B., Van Aelst L. Rho GTPases: signaling, migration, and invasion. Exp Cell Res. 2000 Nov 25; 261(1): 112. doi: 10.1006/excr.2000.5049.

Field J.K., Spandidos D.A. The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis (review). Anticancer Res. 1990; 10(1): 122.

Sato T., Akiyama F., Sakamoto G., Kasumi F., Nakamura Y. Accumulation of genetic alterations and progression of primary breast cancer. Cancer Res. 1991; 51(21): 57945799.

Benz C.C., Scott G.K., Santos G.F., Smith H.S. Expression of c-myc, c-Ha-ras1, and c-erbB-2 proto-oncogenes in normal and malignant human breast epithelial cells. J Natl Cancer Inst. 1989 Nov 15; 81(22): 17049.

Frame M.C., Brunton V.G. Advances in Rho-dependent actin regulation and oncogenic transformation. Curr Opin Genet Dev. 2002; 12(1): 3643.

Price L.S., Collard J.G. Regulation of the cytoskeleton by Rhofamily GTPases: implications for tumour cell invasion. Semin Cancer Biol. 2001; 11(2): 167173. doi: 10.1006/scbi.2000.0367.

Denoyelle C., Hong L., Vannier J.P., Soria J., Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and - independent effects. Br J Cancer. 2003 May 19; 88(10): 163140. doi: 10.1038/sj.bjc.6600925.

Sahai E., Marshall C.J. RHO-GTPases and cancer. Nat Rev Cancer. 2002; 2(2): 133142. doi: 10.1038/nrc725.

Fritz G., Just I., Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer. 1999; 81(5): 682687.

Hulpiau P., van Roy F. Molecular evolution of the cadherin superfamily. Int J Biochem Cell Biol. 2009 Feb; 41(2): 34969. doi: 10.1016/j.biocel.2008.09.027.

Gumbiner B.M. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol. 2005 Aug; 6(8): 62234.

Tepass U. Genetic analysis of cadherin function in animal morphogenesis. Curr Opin Cell Biol. 1999; 11(5): 540548.

Wheelock M.J., Jensen P.J. Regulation of keratinocyte intercellular junction organization and epidermal morphogenesis by E-cadherin. J Cell Biol. 1992 Apr; 117(2): 41525.

Jeanes A., Gottardi C.J., Yap A.S. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene. 2008 Nov 24; 27(55): 69209. doi: 10.1038/onc.2008.343.

Shapiro L., Weis W.I. Structure and biochemistry of cadherins and catenins. Cold Spring Harb Perspect Biol. 2009 Sep; 1(3): a003053. doi: 10.1101/cshperspect.a003053.

Perez-Moreno M., Fuchs E. Catenins: keeping cells from getting their signals crossed. Dev Cell. 2006; 11(5): 601612.

Duprey P., Paulin D. What can be learned from intermediate filament gene regulation in the mouse embryo. Int J Dev Biol. 1995; 39(3): 443457.

Stewart M. Intermediate filament structure and assembly. Curr Opin Cell Biol. 1993; 5(1): 311.

Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press, 1996. 128.

Lacassagne A.L. Apparition de cancers de la mamelle chez la souris mâle soumiseàdes injections de folliculine. Compt Rend Acad Sci. 1932; 195: 630632.

De Mascarel I., MacGrogan G. Management of breast epithelial atypia. Ann Pathol. 2007; 27(3): 182194.

Spandidos D.A., Yiagnisis M., Papadimitriou K., Field J.K. ras, c-myc and c-erbB-2 oncoproteins in human breast cancer. Anticancer Res. 1989; 9(5): 13851393.

Giltnane J.M., Balko J.M. Rationale for targeting the Ras/MAPK pathway in triple- negative breast cancer. Discov Med. 2014; 17(95): 275283.

Calaf G.M., Abarca-Quinones J. Ras protein expression as a marker for breast cancer. Oncol Lett. 2016; 11(6): 36373642. doi: 10.3892/ol.2016.4461.

Malumbres M., Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003 Jun; 3(6): 45965. doi: 10.1038/nrc1097. doi: 10.1038/nrc1097.

Spandidos D.A., Agnantis N.J. Human malignant tumours of the breast, as compared to their respective normal tissue, have elevated expression of the Harvey ras oncogene. Anticancer Res. 1984; 4(45): 269272.

Agnantis N.J., Parissi P., Anagnostakis D., Spandidos D.A. Comparative study of Harvey-ras oncogene expression with conventional clinicopathologic parameters of breast cancer. Oncology. 1986; 43(1): 3639. doi: 10.1159/000226101.

Agnantis N.J., Petraki C., Markoulatos P., Spandidos D.A. Immunohistochemical study of the ras oncogene expression in human breast lesions. Anticancer Res. 1986; 6(5): 11571160.

Efremidis A.P., Agnantis N.J., Patra F., Papadopoulou C., Spandidos D.A. Clinical significance of elevated p21 ras oncogene expression in breast cancer patients. Cancer J. 1989; 2(9): 288291.

Candlish W., Kerr I.B., Simpson H.W. Immunocytochemical demonstration and significance of p21 ras family oncogene product in benign and malignant breast disease. J Pathol. 1986; 150(3): 163167. doi: 10.1002/path.1711500303.

Going J.J., Anderson T.J., Wyllie A.H. Ras p21 in breast tissue: associations with pathology and cellular localisation. Br J Cancer 1992; 65(1): 4550.

Gilles C., Polette M., Zahm J.M., Tournier J.M., Volders L., Foidart J.M., Birembaut P. Vimentin contributes to human mammary epithelial cell migration. J Cell Sci. 1999; 112 (Pt 24): 46154625.

Calaf G.M., Balajee A.S., Montalvo-Villagra M.T., Leon M., Daniela N.M., Alvarez R.G., Roy D., Narayan G., Abarca-Quinones J. Vimentin and Notch as biomarkers for breast cancer progression. Oncol Lett. 2014; 7(3): 721727. doi: 10.3892/ol.2014.1781.

The authors declare that there are no conflicts of interest present.